Nir Peled

Citado por

	Total	Desde 2018
Citas	34400	29003
Índice h	72	56
Índice i10	177	154

7000

3500

1750

5250

20072008200920102011201220132014201520162017201820192020202120222023108 126 176 192 244 307 390 503 536 621 1531 2692 3641 4993 6023 5955 5383

Acceso público

Ver todo

32 artículos

2 artículos

disponibles

no disponibles

Basado en requisitos de financiación

Coautores

Giora PillarProfessor of sleep research and pediatricsDirección de correo verificada de technion.ac.il
Peretz LaviePresident, Technion-Israel institute of TechnologyDirección de correo verificada de technion.ac.il
Alexa SchrockDirección de correo verificada de foundationmedicine.com
Garrett M FramptonFoundation Medicine Inc.Dirección de correo verificada de foundationmedicine.com
Meggie HakimDirección de correo verificada de intel.com
Sai-Hong Ignatius OuUniversity of California IrvineDirección de correo verificada de uci.edu
Daniel SW TanNational Cancer Centre SingaporeDirección de correo verificada de nccs.com.sg
Doron LipsonCSO, Ultima GenomicsDirección de correo verificada de ultimagen.com
Alexander DrilonMemorial Sloan Kettering Cancer CenterDirección de correo verificada de mskcc.org
Yaacov Richard LawrenceDirector, Center for Translational Research in Radiation Oncology, Sheba Medical Center, IsraelDirección de correo verificada de sheba.health.gov.il
Silvio PITLIKVisiting Scientist, Weizmann Institute of ScienceDirección de correo verificada de weizmann.ac.il
luis raezMemorial Cancer Institute/Florida International UniversityDirección de correo verificada de mhs.net
Gabi TarcicVice president, Research and Development, NovellusDxDirección de correo verificada de novellusdx.com
julien mazieresCHU TOULOUSE, INSERM UMR1037, Université Paul SabatierDirección de correo verificada de chu-toulouse.fr
Shaye KivityRheumatology, Tel HashomerDirección de correo verificada de sheba.health.gov.il
Ming TsaoProfessor of Laboratory Medicine and Pathobiology, University of Toronto, Senior Scientist and Consultant Pathologist, Princess Dirección de correo verificada de uhn.ca
avi shupakFaculty of Medicine, Technion, Haifa, IsraelDirección de correo verificada de 012.net.il
Oded Edelheit, Ph.D.NovellusDxDirección de correo verificada de progen.co.il
Mathias ProkopProfessor of Radiology, RadboudumcDirección de correo verificada de radboudumc.nl
Tetsuya MitsudomiKindai UniversityDirección de correo verificada de med.kindai.ac.jp

Seguir

Nir Peled

Head, Shaare Zedek Cancer Center, Jerusalem, Israel

Dirección de correo verificada de szmc.org.il - Página principal

Precision Oncology Lung Cancer Thoracic Malignancies Translation Research


Título Ordenar por citas Ordenar por año Ordenar por título	Citado por Citado por	Año
Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ... New England Journal of Medicine 375 (19), 1823-1833, 2016	8852	2016
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer L Gandhi, D Rodríguez-Abreu, S Gadgeel, E Esteban, E Felip, ... New England journal of medicine 378 (22), 2078-2092, 2018	5223	2018
Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater M Reck, D Rodríguez-Abreu, A Robinson, R Hui, T Csoszi, A Fulop, ...	1286	2019
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018	1146	2018
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ... Annals of Oncology 30 (8), 1321-1328, 2019	913	2019
Volatile organic compounds of lung cancer and possible biochemical pathways M Hakim, YY Broza, O Barash, N Peled, M Phillips, A Amann, H Haick Chemical reviews 112 (11), 5949-5966, 2012	813	2012
Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer S Gadgeel, D Rodríguez-Abreu, G Speranza, E Esteban, E Felip, ... Journal of clinical oncology 38 (14), 1505-1517, 2020	808	2020
Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC C Rolfo, PC Mack, GV Scagliotti, P Baas, F Barlesi, TG Bivona, RS Herbst, ... Journal of thoracic oncology 13 (9), 1248-1268, 2018	588	2018
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ... New England Journal of Medicine 383 (9), 813-824, 2020	581	2020
Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score≥ 50% M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ... Journal of Clinical Oncology 39 (21), 2339, 2021	496	2021
Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules MK Nakhleh, H Amal, R Jeries, YY Broza, M Aboud, A Gharra, H Ivgi, ... ACS nano 11 (1), 112-125, 2017	453	2017
Biomarkers in lung cancer screening: achievements, promises, and challenges LM Seijo, N Peled, D Ajona, M Boeri, JK Field, G Sozzi, R Pio, JJ Zulueta, ... Journal of Thoracic Oncology 14 (3), 343-357, 2019	363	2019
Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations AB Schrock, GM Frampton, J Suh, ZR Chalmers, M Rosenzweig, ... Journal of Thoracic Oncology 11 (9), 1493-1502, 2016	358	2016
Nocturnal ischemic events in patients with obstructive sleep apnea syndrome and ischemic heart disease: effects of continuous positive air pressure treatment N Peled, EG Abinader, G Pillar, D Sharif, P Lavie Journal of the American College of Cardiology 34 (6), 1744-1749, 1999	334	1999
Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry O Gautschi, J Milia, T Filleron, J Wolf, DP Carbone, D Owen, R Camidge, ... Journal of Clinical Oncology 35 (13), 1403, 2017	332	2017
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open … JR Brahmer, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ... The Lancet Oncology 18 (12), 1600-1609, 2017	326	2017
ESR/ERS white paper on lung cancer screening HU Kauczor, L Bonomo, M Gaga, K Nackaerts, N Peled, M Prokop, ... European radiology 25, 2519-2531, 2015	274	2015
Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer C Rolfo, P Mack, GV Scagliotti, C Aggarwal, ME Arcila, F Barlesi, T Bivona, ... Journal of Thoracic Oncology 16 (10), 1647-1662, 2021	271	2021
Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors E Izumchenko, K Paz, D Ciznadija, I Sloma, A Katz, D Vasquez-Dunddel, ... Annals of Oncology 28 (10), 2595-2605, 2017	256	2017
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 D Rodríguez-Abreu, SF Powell, MJ Hochmair, S Gadgeel, E Esteban, ... Annals of Oncology 32 (7), 881-895, 2021	249	2021

El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.

Artículos 1–20

Citas por año

Citas duplicadas

Citas combinadas

Añadir coautoresCoautores

Seguir

Citado por

Coautores